- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Overview
This bill seeks to reverse FDA rule changes that loosened restrictions on mifepristone (the abortion pill), including allowing mail delivery and use without in-person doctor visits. Christian families who hold pro-life convictions would be directly affected by changes to abortion access and availability.
Law Today
In January 2023, the Food and Drug Administration modified the risk evaluation and mitigation strategy (REMS) for mifepristone, an abortion drug. The bill targets those specific FDA modifications.
If Passed
If enacted, this bill would reverse the FDA's January 2023 changes to the mifepristone REMS, likely restoring more restrictive requirements for how the drug can be dispensed and used. This would make chemical abortion less accessible by reinstituting prior safety and distribution protocols.
AI-generated from the bill text — verify against the official text.
Should I support this?
- Strongly Oppose
- Likely Oppose
- Neutral
- This billLikely Support
- Strongly Support
Likely Support
This bill would restore federal constraints on an abortion drug, which aligns with Christian pro-life convictions. Christian parents who believe in protecting unborn life would generally view this as a helpful reassertion of legal guardrails against chemical abortion.
AI assessment using F3’s editorial criteria — faith, family, and freedom. This is F3’s policy judgment; verify the provisions in the official bill text.
Likely supporters & opponents
Likely support
- pro-life groups and organizations — Reversing the FDA's permissive changes protects unborn life by making abortion-inducing drugs harder to obtain and use.
- religious-liberty and Christian advocacy organizations — Stronger regulations on abortion drugs align with Christian convictions about the value of unborn life and allow conscience-based objections to participation.
Likely opposition
- abortion-rights and reproductive-freedom organizations — Restoring stricter REMS rules restricts women's access to a legally approved medication and their autonomy in reproductive decisions.
- medical associations — Tighter restrictions on mifepristone contradict clinical evidence and physician judgment about safe dispensing practices.
AI-inferred typical positions based on the bill’s substance — general stakeholder categories, not confirmed endorsements.
Official summary
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Sponsors
- Diana Harshbarger (R)
- Kevin Hern (R)
- Mike Bost (R)
- Mary Miller (R)
- Randy Weber (R)
- Brian Babin (R)
- John Moolenaar (R)
- Daniel Webster (R)
- James Baird (R)
- Clay Higgins (R)
- Randy Feenstra (R)
- Rudolph Yakym III (R)
- Andy Biggs (R)
- Gary Palmer (R)
- Michael Guest (R)
- Andy Harris (R)
- Keith Self (R)
- Sheri Biggs (R)
- Mark Messmer (R)
Status timeline
- 2025-01-23Referred to the House Committee on Energy and Commerce.H
- 2025-01-23Introduced in HouseH
H = House · S = Senate · A = Assembly